From Globe Newswire:

AnaptysBio, Inc., a biotech company, announced that Daniel Faga will present at the Guggenheim Biotechnology Conference. The event will be a fireside chat on Feb. 7, 2024, at 9:30am ET, and will be available via a live webcast on Anaptys’ investor website. Anaptys is focused on developing innovative immunology therapeutics, with several products in various stages. Among these are rosnilimab, an immune cell modulator in a Phase 2b trial for rheumatoid arthritis and ulcerative colitis, and ANB032, a BTLA agonist in a Phase 2b trial for atopic dermatitis. Additionally, Anaptys has two cytokine antagonists available for out-licensing. For more details, visit their website or connect with them on LinkedIn and X. If you have any questions, please contact Nick Montemarano at 858.732.0178 or email [email protected].



Read more: Anaptys to Present at Guggenheim’s 6th Annual Biotechnology